The entire split between the two forms comes down to one structural feature and the pharmacokinetics it produces. CJC-1295 with DAC carries a Drug Affinity Complex, a maleimidoproprionic-acid tail that binds covalently to circulating serum albumin after injection and stretches the reported plasma half-life from minutes to roughly six to eight days; the form without DAC is the same GHRH(1-29) sequence stripped of that tail, chemically identical to the older research compound mod GRF(1-29), and it clears within about thirty minutes. Neither form is an approved therapeutic drug. Both are research chemicals not authorized for human therapeutic use, and the choice between them in a research setting turns on whether a protocol is built to study sustained or pulsatile stimulation of the GH axis.
| Criteria | With DAC | Without DAC |
|---|---|---|
| Half-life | Roughly 6 to 8 days | About 30 minutes |
| GH/IGF-1 pattern | Continuous elevated plateau | Single sharp pulse |
| Dosing cadence | Once or twice weekly | One or more times daily |
| Regulatory status | Unapproved research chemical | Unapproved research chemical |
The albumin-binding DAC tail is the single structural difference between the two forms, extending the reported half-life from about thirty minutes without DAC to roughly six to eight days with DAC, and neither form is approved for human therapeutic use.
The shared active sequence is the thing most readers get wrong about this comparison; the DAC adds nothing to the GHRH portion of the molecule. The Drug Affinity Complex is a maleimidoproprionic acid (MPA) linker on the C-terminus, and its reactive maleimide group forms a covalent thioether bond with the single free thiol (Cys34) on circulating human serum albumin, turning the body's most abundant plasma protein into a long-lived carrier. Both forms already share a stabilized core carrying four substitutions against native GHRH(1-29), most importantly a D-alanine at position 2 that resists DPP-IV cleavage.
The DAC modification adds no change to the active GHRH sequence and instead appends a single maleimidoproprionic-acid tail that bonds covalently to albumin's Cys34 residue, converting a fast-clearing peptide into a long-circulating albumin-bound complex.
The clearance gap is the most quantitatively dramatic difference between the forms and the source of nearly every downstream contrast. Without DAC, the unprotected peptide is filtered by the kidney and degraded by circulating peptidases on the order of a thirty-minute half-life, so its growth-hormone-releasing effect is essentially finished within a couple of hours. With DAC, the albumin tether makes the complex too large for glomerular filtration and shields it from most proteases; published reports describe a terminal half-life of roughly six to eight days, with growth hormone and IGF-1 elevations and multi-fold sustained IGF-1 increases persisting for a week or more after a single dose.
The non-DAC form carries a circulating half-life of about thirty minutes and a dosing window measured in hours, while the albumin-bound DAC form reports a terminal half-life of roughly six to eight days with sustained IGF-1 elevation persisting a week or more after a single dose.
The naming tangle exists because two separate naming lineages converged on the same molecules, and the result is a source of frequent confusion. In the original developer literature the designation CJC-1295 referred specifically to the DAC-conjugated, long-acting compound, since the drug-affinity-complex technology was the whole point of the CJC numbering; the short-acting peptide of the same stabilized GHRH(1-29) sequence was historically described as modified GRF(1-29), or mod GRF 1-29. When these peptides entered the research-chemical marketplace, vendors began labeling the short-acting compound "CJC-1295 without DAC" because it shares the same core sequence, which is technically defensible but blurs the original distinction.
The "without DAC" product and mod GRF(1-29) are the same molecule under two names, so primary research using mod GRF(1-29) terminology and vendor labels using the with/without DAC framing describe two compounds, not three: a short-acting sequence and that same sequence plus an albumin-binding tail.
Endogenous growth hormone is secreted in discrete pulses, with the largest bursts during slow-wave sleep and pronounced troughs between them, and that pulsatility is thought to be biologically meaningful for tissue signaling rather than incidental. The non-DAC form respects that rhythm: clearing within roughly half an hour, it prompts the pituitary to release a single sharp burst and then washes out, leaving the natural inter-pulse troughs intact. The DAC form does the opposite, its multi-day presence raising the baseline so that growth hormone is elevated in a constant, smeared-out fashion often described colloquially as a GH bleed, which in turn drives IGF-1 to a prolonged plateau measured over days.
| Pattern | Without DAC | With DAC |
|---|---|---|
| GH release shape | Single sharp burst | Constant smeared elevation |
| Inter-pulse troughs | Preserved | Erased |
| IGF-1 response | Transient, follows each burst | Prolonged days-long plateau |
The non-DAC form preserves the natural pulsatile GH rhythm by producing a single sharp burst that washes out within roughly thirty minutes, while the DAC form's multi-day presence raises the baseline into a continuous GH "bleed" that drives IGF-1 to a prolonged plateau.
Dosing cadence is a direct readout of half-life, so the two forms sit at opposite ends of the frequency spectrum in published research protocols. The DAC form, with its multi-day persistence, is described as administered roughly once or twice per week, since a single dose maintains elevated growth hormone and IGF-1 across that interval and additional doses would only stack the plateau higher without a physiological reset. The non-DAC form, clearing within about thirty minutes, is described as administered one to multiple times per day, frequently timed to moments when endogenous GH secretion is naturally favored, such as before sleep or away from carbohydrate-rich meals that blunt the GH response.
Published protocols describe the DAC form as dosed once or twice weekly and the non-DAC form as dosed one to several times daily, a frequency split that follows directly from the six-to-eight-day versus thirty-minute half-life difference.
Any side-effect comparison has to open with the limitation that neither form is an approved drug and human safety data are thin, so much of what is described comes from small studies, animal work, and reported user experience rather than robust clinical trials. Within that limit, the commonly cited effects shared by both forms include transient injection-site reactions, flushing, headache, and fluid retention, the last reflecting growth hormone's known sodium- and water-handling effects. The forms diverge mainly in the theoretical risks tied to their pharmacokinetic shape: the sustained DAC form keeps IGF-1 continuously elevated, and chronic IGF-1 elevation is the focus of the most serious theoretical concerns because IGF-1 is a growth and proliferation signal.
Neither form has a long-term human safety record, and the most serious theoretical concern centers on the DAC form's continuous IGF-1 elevation, which is discussed in connection with edema, joint discomfort, insulin resistance, and a hypothetical risk of promoting abnormal cell growth.
A GHRP such as ipamorelin or GHRP-6 acts on the ghrelin/growth-hormone-secretagogue receptor, a pathway separate from the GHRH receptor a CJC-1295 analog targets, and the two pathways act synergistically on the pituitary to produce a larger growth-hormone release than either alone. That synergy is most coherent with the short-acting non-DAC form because both compounds can be timed to fire together, the GHRH analog priming the somatotrophs while the GHRP amplifies release and suppresses somatostatin, generating a single large, clean, synchronized pulse that then subsides. Stacking a GHRP with the sustained DAC form is considered less logical by many practitioners, since the DAC compound already holds GHRH-receptor stimulation continuously elevated and the GHRP would add a spike onto an already-raised plateau rather than build a defined burst.
The synergistic GHRH-plus-GHRP pairing is documented as coherent with the short-acting non-DAC form because both can be timed to fire together for a single synchronized pulse, whereas pairing a GHRP with the continuously elevated DAC plateau is widely described as redundant.
On the regulatory dimension the two forms are treated essentially the same: both are unapproved investigational peptides with no marketing approval as therapeutic drugs from major regulators such as the U.S. Food and Drug Administration. The DAC compound did enter early clinical investigation under its original developer but did not progress to approval, and development as a marketed product was not completed. As a result both peptides circulate through the research-chemical channel, sold labeled for laboratory or research use only and explicitly not for human consumption, and anti-doping authorities treat GHRH analogs of this class as prohibited in sport at all times.
Neither the with-DAC nor the without-DAC form is approved for human therapeutic use; both circulate as Research Use Only research chemicals not for human consumption and are prohibited in sport at all times, so the choice between them is a research-design question rather than a difference in legal standing.
Selecting between the forms is fundamentally a question of what a protocol is built to model, and the decision falls cleanly along the sustained-versus-pulsatile axis. A protocol aiming to study a continuously elevated growth-hormone and IGF-1 environment, or simply to minimize dosing burden with a once- or twice-weekly schedule, fits the DAC form, whose albumin tether delivers exactly that plateau. A protocol aiming to reproduce the body's natural pulsatile rhythm, to investigate discrete secretory events, or to pair the GHRH analog with a GHRP for synchronized bursts fits the non-DAC short-acting form despite its requirement for frequent daily administration.
Because neither form is approved for human therapeutic use, the selection is properly framed as an experimental-design tradeoff, with the DAC form fitting protocols that model sustained GH/IGF-1 elevation or minimal dosing burden and the non-DAC form fitting protocols that model pulsatile signaling or GHRP-synchronized bursts.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
